Caredx committed to delivering clinical innovation to the transplant patient and physician community

Brisbane, calif.--( business wire )--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary of allosure®, the groundbreaking, non-invasive donor-derived cell-free dna (dd-cfdna) surveillance solution used to measure allograft injury in solid organ transplant recipients. allosure along with allomap® represent disruptive innovations in the field of solid organ transplant.
CDNA Ratings Summary
CDNA Quant Ranking